• Center on Health Equity and Access
  • Clinical
  • Health Care Cost
  • Health Care Delivery
  • Insurance
  • Policy
  • Technology
  • Value-Based Care

AJMC® in the Press, August 2, 2019

Article

Coverage of our peer-reviewed research and news reporting in the healthcare and mainstream press.

Becker’s Hospital Review and Security Magazine cited a study published in The American Journal of Managed Care® (AJMC®) that explored data breaches in hospitals. The study, “Data Breach Locations, Types, and Associated Characteristics Among US Hospitals,” found that paper and films were the most frequent location of breached data, occurring in 65 hospitals during the study period, whereas network servers were the least common location, but their breaches affected the most patients overall.

An article from the Pittsburgh Post-Gazette referenced an AJMC® supplement regarding the opioid epidemic. The supplement, “Deaths, Dollars, and Diverted Resources: Examining the Heavy Price of the Opioid Epidemic,” includes 9 articles exploring the economic burden of the opioid epidemic on the states, and more. The supplement was also picked up by The Heartland Institute.

The National Pharmaceutical Council’s Monday CER Daily Newsfeed included an AJMC® interview with R. Brett McQueen, PhD, assistant professor, Department of Clinical Pharmacy, Pharmaceutical Outcomes Research, Skaggs School of Pharmacy and Pharmaceutical Sciences at the University of Colorado. During the interview, McQueen discussed the need to account for a myriad of criteria when determining cost effectiveness.

Thursday’s CER Daily Newsfeed included AJMC®’s interview with Jeroen Jansen, PhD, lead scientific advisor, Open-Source Value Project, Innovation and Value Initiative, in which he discussed challenges with today’s approaches to value assessment. The newsfeed also included the article “Ibrutinib—Rituximab Improves Survival Compared With Current Treatment for Chronic Lymphocytic Leukemia,” which reported on study findings showing the combination of ibrutinib and rituximab keeps patients with a common form of leukemia alive and disease free longer than the current treatment regimen.

Related Videos
Amitkumar Mehta, MD, MBA
Alma Habib, MD
Jennifer Vaughn, MD, The Ohio State University Comprehensive Cancer Center
Sarah Wall, MD
Adam Kittai MD
Fabian Lang, MD, Goethe Hospital, Germany
Wojciech Jurczak, MD, PhD
Fabian Lang, MD, of Goethe University Hospital in Frankfurt, Germany
Dr Fabian Lang of Goethe University Hospital in Frankfurt, Germany
Related Content
© 2024 MJH Life Sciences
AJMC®
All rights reserved.